An overlapping kinase and phosphatase docking site regulates activity of the retinoblastoma protein

Nature Structural and Molecular Biology

Volumn 17, Issue 9, 2010, Pages 1051-1057

  Hirschi, Alexander ^a   Cecchini, Matthew ^b   Steinhardt, Rachel C ^a   Schamber, Michael R ^a   Dick, Frederick A ^b   Rubin, Seth M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A; CYCLIN DEPENDENT KINASE; PHOSPHOPROTEIN PHOSPHATASE 1; RETINOBLASTOMA PROTEIN; CDK2 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE 2; PROTEIN BINDING;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL CYCLE ARREST; CRYSTAL STRUCTURE; ENZYME ACTIVITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; CELL CYCLE; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; GENETICS; HUMAN; METABOLISM; PHOSPHORYLATION; PROTEIN DOMAIN; X RAY CRYSTALLOGRAPHY;

CELL CYCLE; CELL LINE; CRYSTALLOGRAPHY, X-RAY; CYCLIN-DEPENDENT KINASE 2; HUMANS; MODELS, MOLECULAR; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN PHOSPHATASE 1; RETINOBLASTOMA PROTEIN;

EID: 77956340499     PISSN: 15459993     EISSN: 15459985     Source Type: Journal    
DOI: 10.1038/nsmb.1868     Document Type: Article

References (50)

1. Dyson, N. The regulation of E2F by pRB-family proteins. Genes Dev. 12, 2245-2262 (1998).
2. Weinberg, R.A. The retinoblastoma protein and cell cycle control. Cell 81, 323-330 (1995).
3. Brehm, A. et al. Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature 391, 597-601 (1998).
4. Kennedy, B.K. et al. Histone deacetylase-dependent transcriptional repression by pRB in yeast occurs independently of interaction through the LXCXE binding cleft. Proc. Natl. Acad. Sci. USA 98, 8720-8725 (2001).
5. Nielsen, S.J. et al. Rb targets histone H3 methylation and HP1 to promoters. Nature 412, 561-565 (2001).
6. Zhang, H.S. et al. Exit from G1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF. Cell 101, 79-89 (2000).
7. Adams, P.D. Regulation of the retinoblastoma tumor suppressor protein by cyclin/cdks. Biochim. Biophys. Acta 1471, M123-M133 (2001).
8. Harbour, J.W., Luo, R.X., Dei Santi, A., Postigo, A.A. & Dean, D.C. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 98, 859-869 (1999).
9. Wu, J.Q. et al. PP1-mediated dephosphorylation of phosphoproteins at mitotic exit is controlled by inhibitor-1 and PP1 phosphorylation. Nat. Cell Biol. 11, 644-651 (2009).
10. Ludlow, J.W., Glendening, C.L., Livingston, D.M. & DeCarprio, J.A. Specifc enzymatic dephosphorylation of the retinoblastoma protein. Mol. Cell. Biol. 13, 367-372 (1993).
11. Ludlow, J.W., Shon, J., Pipas, J.M., Livingston, D.M. & DeCaprio, J.A. The retinoblastoma susceptibility gene product undergoes cell cycle-dependent dephosphorylation and binding to and release from SV40 large T. Cell 60, 387-396 (1990).
12. Krucher, N.A. et al. Dephosphorylation of Rb (Thr-821) in response to cell stress. Exp. Cell Res. 312, 2757-2763 (2006).
13. Dou, Q.P., An, B. & Will, P.L. Induction of a retinoblastoma phosphatase activity by anticancer drugs accompanies p53-independent G1 arrest and apoptosis. Proc. Natl. Acad. Sci. USA 92, 9019-9023 (1995).
14. Classon, M. & Harlow, E. The retinoblastoma tumour suppressor in development and cancer. Nat. Rev. Cancer 2, 910-917 (2002).
15. Sherr, C.J. Cancer cell cycles. Science 274, 1672-1677 (1996).
16. Morgan, D.O. Principles of CDK regulation. Nature 374, 131-134 (1995).
17. Broceno, C., Wilkie, S. & Mittnacht, S. RB activation defect in tumor cell lines. Proc. Natl. Acad. Sci. USA 99, 14200-14205 (2002).
18. Durfee, T. et al. The retinoblastoma protein associates with the protein phosphatase type 1 catalytic subunit. Genes Dev. 7, 555-569 (1993).
19. Cohen, P.T. Protein phosphatase 1-targeted in many directions. J. Cell Sci. 115, 241-256 (2002).
20. Terrak, M., Kerff, F., Langsetmo, K., Tao, T. & Dominguez, R. Structural basis of protein phosphatase 1 regulation. Nature 429, 780-784 (2004).
21. Egloff, M.P. et al. Structural basis for the recognition of regulatory subunits by the catalytic subunit of protein phosphatase 1. EMBO J. 16, 1876-1887 (1997).
22. Kiss, A. et al. Myosin phosphatase interacts with and dephosphorylates the retinoblastoma protein in THP-1 leukemic cells: its inhibition is involved in the attenuation of daunorubicin-induced cell death by calyculin-A. Cell. Signal. 20, 2059-2070 (2008).
23. Nelson, D.A., Krucher, N.A. & Ludlow, J.W. High molecular weight protein phosphatase type 1 dephosphorylates the retinoblastoma protein. J. Biol. Chem. 272, 4528-4535 (1997).
24. Tamrakar, S. & Ludlow, J.W. The carboxyl-terminal region of the retinoblastoma protein binds non-competitively to protein phosphatase type 1α and inhibits catalytic activity. J. Biol. Chem. 275, 27784-27789 (2000).
25. Vietri, M., Bianchi, M., Ludlow, J.W., Mittnacht, S. & Villa-Moruzzi, E. Direct interaction between the catalytic subunit of protein phosphatase 1 and pRb. Cancer Cell Int. 6, 3 (2006).
26. Rubin, S.M., Gall, A.L., Zheng, N. & Pavletich, N.P. Structure of the Rb C-terminal domain bound to E2F1-DP1: a mechanism for phosphorylation-induced E2F release. Cell 123, 1093-1106 (2005).
27. Adams, P.D. et al. Retinoblastoma protein contains a C-terminal motif that targets it for phosphorylation by cyclin-cdk complexes. Mol. Cell. Biol. 19, 1068-1080 (1999).
28. Ji, P. et al. An Rb-Skp2-p27 pathway mediates acute cell cycle inhibition by Rb and is retained in a partial-penetrance Rb mutant. Mol. Cell 16, 47-58 (2004).
29. Welch, P.J. & Wang, J.Y. A C-terminal protein-binding domain in the retinoblastoma protein regulates nuclear c-Abl tyrosine kinase in the cell cycle. Cell 75, 779-790 (1993).
30. Xiao, Z.X. et al. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375, 694-698 (1995).
31. Lowe, E.D. et al. Specifcity determinants of recruitment peptides bound to phospho-CDK2/cyclin A. Biochemistry 41, 15625-15634 (2002).
32. Schulman, B.A., Lindstrom, D.L. & Harlow, E. Substrate recruitment to cyclin-dependent kinase 2 by a multipurpose docking site on cyclin A. Proc. Natl. Acad. Sci. USA 95, 10453-10458 (1998).
33. Egloff, M.P., Cohen, P.T., Reinemer, P. & Barford, D. Crystal structure of the catalytic subunit of human protein phosphatase 1 and its complex with tungstate. J. Mol. Biol. 254, 942-959 (1995).
34. Goldberg, J. et al. Three-dimensional structure of the catalytic subunit of protein serine/threonine phosphatase-1. Nature 376, 745-753 (1995).
35. Tamrakar, S., Mittnacht, S. & Ludlow, J.W. Binding of select forms of pRB to protein phosphatase type 1 independent of catalytic activity. Oncogene 18, 7803-7809 (1999).
36. Meiselbach, H., Sticht, H. & Enz, R. Structural analysis of the protein phosphatase 1 docking motif: molecular description of binding specifcities identifes interacting proteins. Chem. Biol. 13, 49-59 (2006).
37. Huang, H.J. et al. Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells. Science 242, 1563-1566 (1988).
38. Hinds, P.W. et al. Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell 70, 993-1006 (1992).
39. Zhu, L. et al. Inhibition of cell proliferation by p107, a relative of the retinoblastoma protein. Genes Dev. 7, 1111-1125 (1993).
40. Margolis, S.S. et al. PP1 control of M phase entry exerted through 14-3-3-regulated Cdc25 dephosphorylation. EMBO J. 22, 5734-5745 (2003).
41. Ferrell, J.E. Jr. Tripping the switch fantastic: how a protein kinase cascade can convert graded inputs into switch-like outputs. Trends Biochem. Sci. 21, 460-466 (1996).
42. Goldbeter, A. & Koshland, D.E. Jr. An amplifed sensitivity arising from covalent modifcation in biological systems. Proc. Natl. Acad. Sci. USA 78, 6840-6844 (1981).
43. Salazar, C. & Hofer, T. Competition effects shape the response sensitivity and kinetics of phosphorylation cycles in cell signaling. Ann. NY Acad. Sci. 1091, 517-530 (2006).
44. Thomson, M. & Gunawardena, J. Unlimited multistability in multisite phosphorylation systems. Nature 460, 274-277 (2009).
45. Tanoue, T., Adachi, M., Moriguchi, T. & Nishida, E. A conserved docking motif in MAP kinases common to substrates, activators and regulators. Nat. Cell Biol. 2, 110-116 (2000).
46. Zhang, Z., Zhao, S., Zirattu, S.D., Bai, G. & Lee, E.Y. Expression of recombinant inhibitor-2 in E. coli and its utilization for the affinity chromatography of protein phosphatase-1. Arch. Biochem. Biophys. 308, 37-41 (1994).
47. Russo, A.A. Purification and reconstitution of cyclin-dependent kinase 2 in four states of activity. Methods Enzymol. 283, 3-12 (1997).
48. Burke, J.R., Deshong, A.J., Pelton, J.G. & Rubin, S.M. Phosphorylation-induced conformational changes in the retinoblastoma protein inhibit E2F transactivation domain binding. J. Biol. Chem. 285, 16286-16293 (2010).
49. Van den Heuvel, S. & Harlow, E. Distinct roles for cyclin-dependent kinases in cell cycle control. Science 262, 2050-2054 (1993).
50. Seifried, L.A. et al. pRB-E2F1 complexes are resistant to adenovirus E1A-mediated disruption. J. Virol. 82, 4511-4520 (2008).